Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-04-19
2011-04-19
Gupta, Anish (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C514S002600
Reexamination Certificate
active
07928199
ABSTRACT:
The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.
REFERENCES:
patent: 4749780 (1988-06-01), Andersson et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4853871 (1989-08-01), Pantoliano et al.
patent: 4868112 (1989-09-01), Toole, Jr.
patent: 4877614 (1989-10-01), Andersson et al.
patent: 5009889 (1991-04-01), Taylor, Jr. et al.
patent: 5082767 (1992-01-01), Hatfield et al.
patent: 5198349 (1993-03-01), Kaufman
patent: 5214033 (1993-05-01), Zimmerman et al.
patent: 5422260 (1995-06-01), Kaufman et al.
patent: 5453937 (1995-09-01), Srinivasan et al.
patent: 5543149 (1996-08-01), Rubin
patent: 5661008 (1997-08-01), Almstedt et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5804181 (1998-09-01), Eibl et al.
patent: 5849688 (1998-12-01), Townes et al.
patent: 5869292 (1999-02-01), Voorberg
patent: 6114148 (2000-09-01), Seed et al.
patent: 6180371 (2001-01-01), Lollar
patent: 6262238 (2001-07-01), Steipe et al.
patent: 6353090 (2002-03-01), Pierschbacher et al.
patent: 6358703 (2002-03-01), Cho et al.
patent: WO 93/20093 (1993-10-01), None
patent: WO 93/20212 (1993-10-01), None
patent: WO 96/21035 (1996-07-01), None
patent: WO 96/36366 (1996-11-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 03/087355 (2003-10-01), None
Clarke et al. “Engineered Disulfide Bonds as Probes of the Folding Pathway of Barnase: Increasing the Stability of Proteins against the Rate of Denaturation,” Biochemistry, vol. 32, pp. 4322-4329. 1993
Gopal et al. “Cavity-Creating Mutation at the Dimer Interface of Plasmodium falciparum Triosephosphate Isomerase: Restoration of Stability by Disulfide Cross-Linking of Subunits,” Biochemistry, vol. 38, pp. 478-486. 1999
File Hcaplus on STN abstract, AN NO 2000:477360. Dandekar, Thomas. Crystal structures of the membrane-binding C2 domain of human coagulation factor V structure of the C2 domain of human factor VIII at 1.5 Å. Chemtracts (2000), vol. 13, No. 6. Abstract only.
Velanker et al. ‘Disulfide engineering at the dimer interface of Lactobacillus casei thymidylate synthase: Crystal structure of the T155C0E188C0C244T mutant.’ Protein Science, vol. 8, pp. 930-933. 1999.
European Search Report for corresponding European application No. EP09159506, Date Mailed—Sep. 16, 2009; Date Completed Search—Sep. 3, 2009 (herein below references cited in the EP Search Report).
Kaufman et al., “Can We Improve On Nature? Super Molecules of Factor VIII”,Haemophilia, Blackwell Science, Oxford, Great Britain, 4(4):370-379 (Jul. 1998).
Hazes et al., “Model Building of Disulfide Bonds in Proteins with Known Three Dimensional Structure”,Protein Engineering, Oxford University Press, Surrey, Great Britain, 2(2):119-125 (1988).
Sowdhamini et al., “Stereochemical Modeling Of Disulfide Bridges. Criteria For Introduction Into Proteins By Site-Directed Mutagenesis”,Protein Engineering, Oxford University Press, Surrey, Great Britain, 3(2):95-103 (1989).
Abkevich et al., “What Can Disulfide Bonds Tell Us About Protein Energetics, Function And Folding: Simulations And Bioinformatics Analysis”,Journal of Molecular Biology, 300(4):975-985 (Jul. 21, 2000).
Dani et al., “MODIP revisited: re-evaluation and refinement of an automated procedure for modeling of disulfide bonds in proteins”,Protein Engineering, 16(3):187-193 (Mar. 2003).
Gale et al., “Interdomain Engineered Disulfide Bond Permitting Elucidation Of Mechanisms Of Inactivation Of Coagulation Factor Va By Activated Protein C”,Protein Science: A Publication Of The Protein Society, 11(9):2091-2101 (Sep. 2002).
Gale et al., “An Engineered Interdomain Disulfide Bond Stabilizes Human Blood Coagulation Factor VIIIa”,Journal of Thrombosis and Haemostatis, 1(9):1966-1971 (2003).
Reiter et al: “Disulfide stabilization of antibody Fv: Computer Predictions and Experimental Evaluation.”Protein Engineering, vol. 8, No. 12 pp. 1323-1331, Dec. 1995.
Aly et al: “Cysteamine Enhances the Procoagulant Activity of Factor VIII-East Hartford A Dysfunctional Protein Due to a Light Chain Thrombin Cleavage Site Mutation Arginine-1689 to Cystein”,Journal of Clinical Investigation, vol. 89, No. 5, pp. 1375-1381, 1992.
Aly et al: “The Substitution of Cystein for Arginine-1689 In Factor VIII-East Hartford Reduces its Procoagulant Activity through Formation of a Disulfide Bond”,Clinical Research, vol. 38 No. 2, p. 427A, 1992.
Pantoliano et al. “Protein Engineering of Substilsin BPN”: Enhanced Stablization Throught the Intorudction of Two Cysteines to Form a Disulfide Bond.Biochemistry, vol. 26, pp. 2077-2082. 1987.
Arai et al. “Characterization of Thrombin Cleavage Site Mutation (ARG 1689 to CYS) in the Factor VIII Gene of Two Unrelated Patients With Cross-Reacting Material-Positive Hemophilia A.”Bloodvol. 75, No. 2, pp. 384-389. Jan. 15, 1990.
Boedeker, B. G. D., “Production Processes of Licensed Recombinant Factor VIII Preparations,”Seminars in Thrombosis and Hemostasis, 27(4):385-394, Aug. 2001.
Bray, G.L. et al., “A Multicenter Study of Recombinant Factor VII (Recombinant): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patents With Hemophilia A,”Blood, 83Q:2428-2435, May 1, 1994.
Brinkhouse, K.M. et al., “Purified human factor VIII procoagulant protein: Comparative hemostatus response after infusions into hemophilic and von Willebrand disease dogs,”Proc. Natl. Acad. Sci. USA, 82:8752-8756, Dec. 1985.
Chao, H. et al., “Sustained expression of human factor VIII in mice using a parvovirus-based vector,”Blood, 95(5): 1594-1599, Mar. 2000.
Chao, H. et al., “Induction of tolerance to human factor VIII in mince,” (httyp://www.ncbi.nlm.nih.gov:80/entrez/q . . . PubMed&list uids=11342466&dopt=Abstract),Blood, 97(10):3311-3312, May 15, 2001.
Choi-Miura, N-H et al. “Purification and Characterization of a Novel Hyaluronan-Binding Protein (PHBP) from Human Plasma: It Has Three EGF, a Kringle and a Serine Protease Domain, Similar to Hepatocyte Factor Activator,”J. Biochem, 119:1157-1165, 1996.
Cochrane, G.G. et al. The Biochemistry and Pathophysiology of the Contact System of Plasma,Advances In Immunology, 33:241-306, 1982.
Colman, R.W. et al., “Biologic Activities of the Contact Factors In Vivo,”Thromb. Haemost, 82:1568-1577, 1999.
Cool, D.E. et al., “Characterization of Human Blood Coagulation Factor XII cDNA,”J. Bio. Chem., 260(25): 13666-13676, Nov. 5, 1985.
Cote, H.C.F. et al., “Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin (desF1),”J. Biol. Chem., 272(10):6194-6200, Mar. 1997.
Dela Cadena, R.A. Wachtfogel, YT and Colman RW. Contact Activation Pathway: Inflammation and Coagulation. InHemostasis and Thrombosis: Basic Principles and Clinical Practice, Third Edition. Eds. RW Colman, J Hirsch, VJ Marder and EW Saltzman. JB Lippincott Company, Philadelphia, 1994.
Doyle, M.F. et al., “Meizothrombin: Active Intermediate Formed during Prothrombinase-Catalyzed Activation of Prothrombin,”Methods Enzymol, 222:299-312,
Gale Andrew J.
Getzoff Elizabeth D.
Griffin John H.
Pellequer Jean-Luc
Fitting Thomas
Gupta Anish
Kwon Evelyn M.
The Scripps Research Institute
Wenk Melissa B.
LandOfFree
Stabilized proteins with engineered disulfide bonds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized proteins with engineered disulfide bonds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized proteins with engineered disulfide bonds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619248